Back to top
more

Mirati Therapeutics, Inc. (MRTX)

(Delayed Data from NSDQ)

$128.88 USD

128.88
366,198

-0.68 (-0.52%)

Updated Aug 7, 2020 04:00 PM ET

After-Market: $129.32 +0.44 (0.34%) 7:57 PM ET

3-Hold of 5     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.33%
17.77%
9.37%
4.88%
1.79%
10.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value F Growth F Momentum F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for MRTX

   

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

Mirati Therapeutics, Inc. [MRTX]

Reports for Purchase

Showing records 1 - 20 ( 85 total )

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

07/17/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

06/23/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

06/09/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

06/01/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/08/2020

Company Report

Pages: 8

1Q20 Results; Sitravatinib OS Data Update Takes Center Stage

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

04/29/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

04/20/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

04/07/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

02/28/2020

Company Report

Pages: 8

4Q19 Results-MRTX849 KRYSTAL Trial Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/24/2020

Company Report

Pages: 7

Mirati Common Stock Offering Closed; Raising PT to $134

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

12/13/2019

Daily Note

Pages: 3

BeiGene Announces Phase 1b Data for Sitravatinib Plus Tislelizumab

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

11/11/2019

Company Report

Pages: 8

Positive Interim Sitravatinib Data Presented at SITC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

11/06/2019

Company Report

Pages: 8

3Q19 Results; All Eyes on MRTX849; Interim Phase 2 Sitravatinib Data at SITC This Weekend

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

10/29/2019

Company Report

Pages: 8

Initial MRTX849 Data Impressive in Our Opinion

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

10/17/2019

Daily Note

Pages: 4

Mirati to Present MRTX849 Data at ACR-NCI-EORTC

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 10.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for MRTX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

08/06/2019

Company Report

Pages: 8

2Q19 Results; KRAS Taking Center Stage but Do Not Forget Sitravatinib

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

06/05/2019

Company Report

Pages: 8

AMG 510 Data at ASCO Gives Us More Confidence in MRTX849; Raising Our PT to $117

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

05/01/2019

Company Report

Pages: 8

Reports 1Q19 Results; Development of Sitravatinib and MRTX849 Remain on Track; Lowering PT by $1

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party

Company: Mirati Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

03/01/2019

Company Report

Pages: 8

Mirati Reports 4Q18 Results; Combination Trials and Pipeline Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 25.00

Research Provided by a Third Party